Connect your AI

Corcept Therapeutics CORT Raw materials

Other financials

Income statement

Revenue$164.9M+4.9%

Gross profit$162.0M+4.7%

Operating income-$49.6M-1,552%

Net income-$31.8M-255%

EPS (diluted)-$0.30-276%

Balance sheet

Cash & equivalents$110.0M+21.1%

Total debt$9.6M+41.0%

Total equity$638.0M-6.6%

Total assets$814.9M-3.7%

Cash flow

Operating cash flow-$16.8M-452%

CapEx$201.0K+93.3%

Free cash flow-$17.0M-464%

Valuation

Market cap$8.58B-64.4%

Enterprise value$8.48B-65.0%

P/E181.2×+1.3×

P/S11.2×-24.0×

Profitability

Gross margin98.3%-0.2pp

Operating margin-1.1%-17.2pp

Net margin6.2%-13.4pp

FCF margin15.6%-10.2pp

Returns & leverage

Return on equity7.2%-14.6pp

Debt / equity0×0.0×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept cort:InventoryRawMaterialCurrentAndNoncurrent.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's raw materials.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Corcept Therapeutics's raw materials?: Corcept Therapeutics (CORT) reported raw materials of $894K in Q1 2026.